Lyell Immunopharma, Inc.
64 articles about Lyell Immunopharma, Inc.
-
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
3/5/2024
Lyell Immunopharma, Inc. announced that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 taking place in San Diego, CA, April 5-10.
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
2/28/2024
Lyell Immunopharma, Inc., a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors reported financial results and business highlights for the fourth quarter and year ended December 31, 2023.
-
Lyell Immunopharma Announces Participation in March 2024 Investor Conferences
2/26/2024
Lyell Immunopharma, Inc., a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that members of its senior management team will present and participate the following upcoming investor conferences:
-
On Friday, the regulator greenlit Iovance's lifileucel to treat advanced melanoma. Prior to the approval, experts told BioSpace that tumor-infiltrating lymphocytes therapies also hold the potential to treat several other solid tumors.
-
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced today that members of its senior management team will present and participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 8:15 am Pacific Time.
-
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
11/9/2023
Lyell Immunopharma, Inc. (Nasdaq: LYEL) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to LYL845, an investigational tumor infiltrating lymphocyte (TIL) product candidate for the treatment of patients with stage IIB-IV melanoma.
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
11/7/2023
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T‑cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the third quarter ended September 30, 2023.
-
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
10/31/2023
Lyell Immunopharma, Inc. is presenting new nonclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer.
-
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
9/27/2023
Lyell Immunopharma, Inc. announced that six abstracts highlighting its broad pipeline of clinical and preclinical product candidates as well as a shortened TIL manufacturing process have been accepted for presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer taking place in San Diego, Nov. 1-5, 2023.
-
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
9/11/2023
Cellares and Lyell Immunopharma announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership program.
-
Lyell Immunopharma to Participate in Upcoming September 2023 Investor Conferences
8/31/2023
Lyell Immunopharma, Inc. announced that members of its senior management team will participate in the following upcoming healthcare conferences:
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
8/8/2023
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the second quarter ended June 30, 2023.
-
Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
7/5/2023
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer.
-
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
6/7/2023
Lyell Immunopharma, Inc. (Nasdaq: LYEL) today announced that members of its senior management team will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14 at 2:00pm PT.
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
5/4/2023
Lyell Immunopharma, Inc., a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors reported financial results and business highlights for the first quarter ended March 31, 2023.
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
2/28/2023
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.
-
Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Lyell Immunopharma, Inc., a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that members of its senior management team will present and participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 4:30 pm Pacific Time.
-
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
12/15/2022
Lyell Immunopharma, Inc. announced that Lynn Seely, MD, a member of the company’s board and former president and chief executive officer (CEO) of Myovant Sciences, has been named Lyell’s president & CEO effective today.
-
Lyell Immunopharma to Participate in BofA Securities Biotech Conference
12/1/2022
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the virtual BofA Securities 2022 Biotech SMID Cap Conference on Thursday, Dec. 8 at 1:40 pm ET.
-
Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series
11/10/2022
Lyell Immunopharma, Inc. announced that members of its senior management team will participate in the Barclays Virtual Fireside Chat Series on Thursday, November 17, at 11 a.m., ET.